Taken these findings together we believe that the efficacy observed in the treated ALL patients warrants a further clinical exploration of dual PI3K/mTOR inhibition potentially as combination therapy with other small molecules or chemotherapeutics. The gene discussed is PIK3CD; the disease is acute lymphoblastic leukemia.